Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II - 17/08/11
, Marcelo Bertolami, MD b, Hugo Ricardo Hernandez Garcia, MD c, Daniel Nul, MD d, Evan A. Stein, MD e, Pierre Theroux, MD f, Robert Weiss, MD g, Valerie A. Cain, MS h, Joel S. Raichlen, MD hAbstract |
Background |
National Cholestesrol Education Program Adult Treatment Panel III guidelines for patients at a high risk of coronary heart disease set a low-density lipoprotein cholesterol (LDL-C) target of <100 mg/dL. This target can be difficult to attain with diet and current therapy.
Methods |
In a 16-week multinational trial, 1993 high-risk patients were randomized to rosuvastatin 20 mg, atorvastatin 10 mg, atorvastatin 20 mg, simvastatin 20 mg, or simvastatin 40 mg for 8 weeks. Patients either remained on starting treatment or switched to lower or milligram-equivalent doses of rosuvastatin for 8 more weeks.
Results |
At 16 weeks, more patients achieved their LDL-C target by switching to rosuvastatin 10 mg than staying on atorvastatin 10 mg (66% vs 42%, P < .001) or simvastatin 20 mg (73% vs 32%, P < .001). Changing to rosuvastatin 20 mg brought more patients to their LDL-C target than staying on atorvastatin 20 mg (79% vs 64%, P < .001) or simvastatin 40 mg (84% vs 56%, P < .001). More very high risk patients achieved an LDL-C target of <70 mg/dL when changed to rosuvastatin from atorvastatin or simvastatin (within-arm comparisons P < .01). More hypertriglyceridemic patients (triglycerides ≥200 mg/dL) met LDL-C, non–high-density lipoprotein cholesterol (non–HDL-C), and apolipoprotein B targets by changing to rosuvastatin. Switching to rosuvastatin produced greater reductions in LDL-C, total cholesterol, non–HDL-C, apolipoprotein B, and lipid ratios. All treatments were well tolerated, with no differences among treatment groups in skeletal muscle, hepatic, or renal toxicity.
Conclusion |
Rosuvastatin 10 or 20 mg is an effective and safe therapeutic option for high-risk patients to achieve their lipid and apolipoprotein targets.
Il testo completo di questo articolo è disponibile in PDF.Mappa
Vol 151 - N° 5
P. 975.e1-975.e9 - Maggio 2006 Ritorno al numero
Articolo precedente
- Missed opportunities in the secondary prevention of myocardial infarction: An assessment of the effects of statin underprescribing on mortality
- Peter C. Austin, Muhammad M. Mamdani, David N. Juurlink, David A. Alter, Jack V. Tu
- Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: Analysis of the Orbofiban in Patients with Unstable coronary Syndromes–Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial
- Shaul Atar, Christopher P. Cannon, Sabina A. Murphy, Salvatore Rosanio, Barry F. Uretsky, Yochai Birnbaum
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?